MedTrace Logo

Sepsis-associated Thrombocytopenia and Platelet Transfusion （STAPT）

NCT07230067 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-01-30

No results posted yet for this study

Summary

Currently, there are no multicenter studies on platelet transfusion for SAT patients, and the benefits and risks of platelet transfusion still require further validation based on large-sample data. In summary, investigating the correlation between platelet transfusion during ICU stay and 28-day mortality in SAT patients, as well as evaluating the impact of platelet transfusion on bleeding, thrombotic events, and inflammation control, is of great significance for optimizing SAT management strategies. This study aims to analyze the effect of platelet transfusion on the prognosis of SAT patients, thereby providing an evidence-based foundation for clinical decision-making.

Conditions

  • Sepsis
  • Sepsis and Coagulopathy

Interventions

OTHER

SAT patients

Whether or not the SAT patients received Platelet infusion

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-15
Primary Completion
2026-12-30
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07230067 on ClinicalTrials.gov